Pediatrics in Review Note to Institutions for Site Subscriptions
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peter, G.
Right arrow Articles by Klein, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peter, G.
Right arrow Articles by Klein, J. O.

Pneumococcal Vaccine

Georges Peter MD1
Jerome O. Klein MD2
 1 Professor of Pediatrics, Brown University School of Medicine, Providence, RI. Dr Peter has been a consultant with Merck & Company and a lecturer supported by Lederle Laboratories
2 Professor of Pediatrics, Boston University School of Medicine, Boston, MA. Dr Klein is a consultant, lecturer, and a grant recipient with Lederle Laboratories

Streptococcus pneumoniae, commonly termed the pneumococcus, is a major pediatric pathogen both in developed and developing countries. Despite the availability of multiple antimicrobials to which this organism is susceptible, it continues to cause significant morbidity and mortality. Recognition of the limitations of antimicrobial therapy in controlling the consequences of infection, particularly among high-risk persons such as those who have underlying pulmonary or cardiovascular disease and the elderly, led to the introduction in the 1970s of a polyvalent, polysaccharide pneumococcal vaccine. As a result, the current indications for vaccination of both children and adults are based on risk factors for severe, potentially life-threatening pneumococcal infections and, in the case of children, the age-related immunogenicity of the polysaccharide antigens of this vaccine. Appropriate use of this vaccine is facilitated by knowledge of the pathogenicity of S pneumoniae, epidemiology of the infections it causes, and the immunogenicity and efficacy of the vaccine.

The limitations of the current pneumococcal vaccine not only affect management of vaccinated patients but also have prompted development of investigational vaccines for use among infants and young children. Polysaccharide-protein conjugate pneumococcal vaccines that have increased immunogenicity in infants are in clinical trials and will be discussed only briefly in this review.




This article has been cited by other articles:


Home page
 PediatricsHome page
S. L. Kaplan, E. O. Mason Jr, W. J. Barson, E. R. Wald, M. Arditi, T. Q. Tan, G. E. Schutze, J. S. Bradley, L. B. Givner, K. S. Kim, et al.
Three-Year Multicenter Surveillance of Systemic Pneumococcal Infections in Children
Pediatrics, September 1, 1998; 102(3): 538 - 545.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics Pediatrics in Review
Copyright © 1996 by the American Academy of Pediatrics.